Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Merit Medical Systems (MMSI)

Merit Medical raises 2025 guidance as Q2 revenue rises 13.2% to $382.5 million

Positive Impact 4 of 5 earnings Written later

Merit Medical reported second-quarter 2025 revenue of $382.5 million, up 13.2% from a year earlier, and raised its full-year 2025 net sales and non-GAAP earnings per share guidance. GAAP earnings per share fell to $0.54 from $0.61, while non-GAAP earnings per share rose to $1.01 from $0.92. The company also named Martha Aronson as its new President and Chief Executive Officer, effective October 3, 2025.

Key points

  • Q2 2025 net sales were $382.5 million, up 13.2%; constant currency revenue, organic, rose 6.7%
  • 2025 net sales guidance raised to $1.495 billion to $1.507 billion from $1.480 billion to $1.501 billion
  • 2025 non-GAAP EPS guidance raised to $3.52 to $3.72 from $3.28 to $3.41
  • Martha Aronson named President and CEO, effective October 3, 2025

The filing

CompanyMerit Medical Systems (MMSI)
Form8-K, current report
Filed with the SECJul 30, 2025, 4:15 PM ET
Accession number0000856982-25-000045

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:05 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.